1 / 20

Brintellix ™ - Vortioxetine

Brintellix ™ - Vortioxetine. Manufacturer: Takeda FDA Approval Date: September 30, 2013. Brintellix ™ - vortioxetine Clinical Application. Indications: Major Depressive Disorder (MDD) Place in therapy: For those with MDD who have failed other drug therapies

ulric
Download Presentation

Brintellix ™ - Vortioxetine

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Brintellix™ - Vortioxetine Manufacturer: Takeda FDA Approval Date: September 30, 2013

  2. Brintellix™ - vortioxetineClinical Application • Indications: • Major Depressive Disorder (MDD) • Place in therapy: • For those with MDD who have failed other drug therapies • Recently, research has come out indicating that vortioxetine may have a cognitive benefit in patients with MDD

  3. Brintellix™ - vortioxetineClinical Application • Contraindications: • Hypersensitivity • Use of MAOIs concurrently, within 21 days of discontinuing vortioxetine, or within 14 days of discontinuing the MAOI • Black Box Warning: • Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (<25) with MDD

  4. Brintellix™ - vortioxetineClinical Application • Warnings and Precautions • Increased bleeding risk due to impaired platelet aggregation • Increased risk of serotonin syndrome • Increased risk of SIADH and hyponatremia • May precipitate a mixed/manic episode in bipolar patients • May cause CNS depression • Angioedema has been reported

  5. Brintellix™ - vortioxetineClinical Application • Pregnancy: • Category C • Lactation: • Excretion in breast milk is unknown; use is not recommended

  6. Brintellix™ - vortioxetineDrug Facts • Pharmacology: • selective serotonin inhibitor • 5-HT1A receptor agonist • partial agonist of 5HT1B • antagonist of 5-HT3 , 5-HT1D, and 5HT7 receptors

  7. Brintellix™ - vortioxetineDrug Facts • Pharmacokinetics:

  8. Brintellix™ - vortioxetineDrug Interactions • Drug Interactions – Precipitant Drugs: • CYP2D6 inhibitors  vortioxetine concentrations • CYP3A4 inducers  vortioxetine concentrations

  9. Brintellix™ - vortioxetineAdverse Effects

  10. Brintellix™ - vortioxetineMonitoring Parameters • Efficacy Monitoring: • Symptom improvement • Toxicity Monitoring: • Monitor for signs and symptoms of serotonin syndrome • Monitor for hyponatremia

  11. Brintellix™ - vortioxetinePrescription Information • Dosing: 5 mg to 20 mg daily • Initial: 10 mg daily • Max: 20 mg daily • Cost: $258 for #30 • Same price for all strengths • Walmart Pharmacy contacted 12/26/2013

  12. Brintellix™ - vortioxetineLiterature Review • A multicenter, double-blind, randomized, placebo-controlled, parallel-group, phase 3 study • [1mg] [5mg] [10mg] [placebo] • Primary Endpoint • Reduction in 24-item Hamilton Depression Rating Scale (HDRS-24) total score Henigsberg N, et al. J Clin Psychiatry. 2012;73:953-59

  13. Brintellix™ - vortioxetineLiterature Review • Secondary Endpoints • Response and remission rates • Sheehan Disability Scale (SDS) • Clinical Global Impressions-Global Improvement scale (CGI-I) • MADRS total score • HDRS-24 total score in subjects with baseline Hamilton Anxiety Rating Scale (HARS) score >20 Henigsberg N, et al. J Clin Psychiatry. 2012;73:953-59

  14. Brintellix™ - vortioxetineLiterature Review • N = 560 • Age 18-75 (average age 46) • MDD of at least 3 months’ duration • MADRS total score > 26 • Patients considered at a significant risk of suicide, had other psychiatric or neurologic conditions, or substance abuse history, or another significant medical illness Henigsberg N, et al. J Clin Psychiatry. 2012;73:953-59

  15. Brintellix™ - vortioxetineLiterature Review Henigsberg N, et al. J Clin Psychiatry. 2012;73:953-59

  16. Brintellix™ - vortioxetineLiterature Review Primary Outcome: Henigsberg N, et al. J Clin Psychiatry. 2012;73:953-59

  17. Brintellix™ - vortioxetineLiterature Review Secondary Outcomes: Henigsberg N, et al. J Clin Psychiatry. 2012;73:953-59

  18. Brintellix™ - vortioxetineIn the News • December 10, 2013: FOCUS • Brintellix was superior to placebo in a composite score of two tests (p<0.0001) • Digit Symbol Substitution Test (DSST) • Rey Auditory Verbal Learning Test (RAVLT) • Both of these tests measure cognitive function in adults with MDD • Patients on Brintellix had improved executive function, speed of processing and attention McIntyre RS, Lophaven S, Olsen CK. Randomized, double-blind, placebo-controlled study of the efficacy of vortioxetine on cognitive dysfunction in adult patients with major depressive disorder (MDD). Neuropsychopharmacology 2013;38:S380-S381 . [Conference abstract] Abstract T160

  19. Brintellix™ - vortioxetineSummary • Brintellix is indicated for treatment of major depressive disorder • The initial dose is typically 10 mg and can be increased to 20 mg as tolerated • Nausea is the most common side effect • Monitor for serotonin syndrome and SIAD/hyponatremia

  20. Brintellix™ - vortioxetineReferences • http://www.us.brintellix.com • Boulenger JP, et al. J Psychopharmacol. 2012;26:1408-16 • Brintellix [package insert]. Deerfield, IL: Takeda Pharmaceuticals Inc.; September 2013. • Henigsberg N, et al. J Clin Psychiatry. 2012;73:953-59 • McIntyre RS, Lophaven S, Olsen CK. Randomized, double-blind, placebo-controlled study of the efficacy of vortioxetine on cognitive dysfunction in adult patients with major depressive disorder (MDD). Neuropsychopharmacology 2013;38:S380-S381. [Conference abstract] Abstract T160

More Related